CD34 and myelodysplastic syndrome: In patients with Diamond-Blackfan anemia (DBA) and myelodysplastic syndrome (MDS), dexamethasone treatment dysregulates ribosome function and increases the number of erythroid cells produced from normal CD34(+) cells and from CD34(+) cells with the types of ribosome dysfunction [45].